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Introduction. Cardiac involvement of myasthenia gravis (MG) accompanies a poor prognosis. In the present study, we aimed
to investigate the relationship between ECG abnormality and cardiac involvement. Methods. Of 178 patients diagnosed with
MG between 2001 and 2013 at our hospital, we retrospectively analyzed consecutive 58 patients who underwent both ECG
and echocardiography and without underlying cardiovascular disease. ECG abnormalities were defined by computer-assigned
Minnesota-codes. Cardiac damage was defined as either (1) ejection fraction (EF) <55% on echocardiography or (2) elevated 𝐸/𝑒󸀠,
the ratio of mitral velocity to early diastolic velocity of the mitral annulus >8 on echocardiography. Results. Thirty-three patients
(56.8%) had ECG abnormality. An elevated 𝐸/𝑒󸀠 was observed in patients with ECG abnormality compared to those without ECG
abnormality (11.2±3.2, 8.7±2.2, resp., 𝑝 = 0.03). Among patients with ECG abnormality, 14 of 15 patients showed cardiac damage.
Among patients without ECG abnormality, 6 of 33 patients showed cardiac damage (𝑝 = 0.003). Reduced EF was observed in five
patients (8.6%) with ECG abnormality and none in patients without ECG abnormality. Conclusions. ECG may aid as the first step
for the further examination of cardiac damage in patients with MG.
1. Introduction
Myasthenia gravis (MG) primarily affects skeletal muscle via
production of autoantibodies against nicotinic acetylcholine
receptors in the motor endplates; heart muscle is a rare
autoimmune target [1, 2]. Patients withMGmay show several
kinds of cardiac involvement, ranging from asymptomatic
changes on electrocardiography (ECG) to ventricular tachy-
cardia, myocarditis, conduction disorder, heart failure, and
sudden death [2–5]. Detection of cardiac involvement in MG
is important because this cardiomyopathy may be treatable
[4, 5]. In the present study, we aimed to investigate the
relationship between ECG abnormality and cardiac damage
by echocardiography in order to aid in early detection and
timely treatment.
2. Methods
Of 178 patients diagnosed with MG between 2001 and 2013
at our hospital, we retrospectively analyzed consecutive 58
patients who underwent both ECG and echocardiographic
examinations and without underlying cardiovascular dis-
ease (ischemic heart disease, valvular heart disease, and
hypertensive heart disease). ECG abnormalities were defined
by standardized computer-assigned Minnesota-codes [6, 7].
Echocardiography was performed by cardiac sonographers
according to the guidelines [8].
Cardiac damage was defined as either (1) ejection fraction
(EF) <55% on echocardiography (the EF of a normal heart
may be between 55% and 70%) according to the practice
guideline [8, 9] or (2) elevated𝐸/𝑒󸀠, the ratio ofmitral velocity
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Table 1: Characteristics of electrocardiographic abnormality.
Characteristic 𝑛 (%) With left ventricledamage, 𝑛
Persistent atrial
fibrillation 6 (10.3) 3
Atrioventricular block 4 (6.8) 3
ST depression 17 (29.3) 9
Negative T wave 17 (29.3) 8
to early diastolic velocity of the mitral annulus (𝐸/𝑒󸀠) >8 on
echocardiography (the 𝐸/𝑒󸀠 of a normal left ventricular end-
diastolic pressure may be <8) [8, 10].
The study conformed to the ethical guidelines of the 1975
Declaration of Helsinki andwas approved by the Institutional
Review Board of Kitano Hospital. All data are expressed as
mean ± SD. Differences between groups were compared by
using the Mann-Whitney 𝑈 test, while categorical variables
were compared by using Pearson’s chi-square test. In all tests,
𝑝 values of <0.05 were considered significant.
3. Results
Thirty-three patients (56.8%) had ECG abnormality: 10.3%
had atrial fibrillation, 6.8% had atrioventricular block, 29.3%
had nonspecific ST depression, and 29.3% had negative T
wave (Table 1). There were no differences in comorbidities
or clinical characteristics of MG patients with or without
ECG abnormality (Table 2). On echocardiography, there was
a difference in 𝐸/𝑒󸀠 between patients with or without ECG
abnormality (11.2 ± 3.2, 8.7 ± 2.2, resp., 𝑝 = 0.03, Table 3).
Among patients with ECG abnormality, 14 of 15 patients
showed the suggested cardiac damage. Among patients with-
out ECG abnormality, 6 of 33 patients showed the suggested
cardiac damage (𝑝 = 0.003, Table 4). The sensitivity of ECG
abnormality for detecting cardiac damage was 0.700 (95%
confidence interval [CI], 0.525–0.836), while its specificity
was 0.711 (95% CI, 0.618–0.782). The positive predictive
value was 0.560 (95% CI, 0.420–0.669), while the negative
predictive value was 0.818 (95% CI, 0.712–0.901).
When we limited the cases by reduced EF, five patients
(8.6%) had reduced EF (EFs of 10%, 26%, 43%, 49%, and 54%,
resp.) with diffuse hypokinesis; all 5 had ECG abnormality
with high 𝐸/𝑒󸀠 values of 12 ± 3.6. Among patients without
ECG abnormality, none of the patients showed reduced EF.
Of the 5 patients with reduced EF, 1 patient with an EF of
30% died of colon cancer, and 4 patients were administered
immunosuppressive therapy. Three of the 4 patients with
EFs of 43%, 47%, and 54%, respectively, had a good clinical
course, while 1 patient with an EF of 10% died of acute
decompensated heart failure approximately 1 month after
self-discontinuation of immunosuppressive therapy.
4. Discussion
Cardiac manifestation is thought to be relatively rare in
MG. However, it has been reported that approximately 16%
of patients with MG have various cardiac manifestations,
such as arrhythmia and heart failure [1]. Autoimmunologic
mechanisms are considered to be contributory to such
cardiac involvement [2], such as the antibody for ryanodine
receptor (RyR), the antibody for both beta 1 and beta 2 adren-
ergic receptors, the anti-titin antibodies, and the antibody
for Kv1.4—a muscular voltage-gated potassium channel [2].
Arrhythmia is the most common clinical manifestation of
unexplained cardiac disease in MG, occurring in as many
as 8% of cases [1], which is consistent with the findings of
the present study. The prevalence of abnormal ECG is also
reported varying from 16% to 88% of patients with MG
[1, 11, 12], probably due to the inclusivity of MG patients
who underwent ECG; however, no demonstration of any
clinical significance was provided. This study validated the
presence of ECG abnormality in patients withMG, including
arrhythmia, conduction abnormality, and the abnormality of
ST portion and T wave. We also showed that a small number
of patients without ECG abnormality demonstrated cardiac
damage, which comprised only diastolic impairment and did
not include systolic impairment. These results implied the
utility of ECG. If the abnormality exists, further examination
by echocardiography may be necessary for the detection of
systolic impairment in patients with MG, which indicates a
poor prognosis but can be treated by immunosuppressant
therapy [1, 2, 4]. Therefore, the presence or absence of ECG
abnormality may be useful as the first step for the further
examination of cardiac damage in patients with MG.
Cardiac investigation in patients with MG with unex-
plained fatigue should comprise a physical examination
including third tone, holosystolic murmurs, ankle swelling,
or lung rales; laboratory findings including brain natriuretic
peptide (BNP) [8–10] and cardiac troponin [4]; 6-minute
walk distance [13]; and echocardiography along with ECG.
Diastolic impairment also affects the exercise intolerance and
it is more likely to cause atrial fibrillation. 𝐸/𝑒󸀠 in particular
closely correlates with left ventricular filling pressure. Several
prominent validation studies have confirmed this correlation
and noted that the prediction of normal or abnormal filling
pressure is most reliable when the ratio is <8 or >15, respec-
tively [14, 15]. In our study, the 𝐸/𝑒󸀠 values were relatively
high (mean: 10.46 ± 3.24) in patients in MG. There is a
possibility that diastolic function was reduced in patients
with MG. The diameter of the left atrium tends to be larger
in patients with ECG abnormality; however, the combined
measurement of BNP or N-terminal pro-BNP levels requires
validation [8–10]. The mechanism underlying the high 𝐸/𝑒󸀠
could be explained, at least partly, by the disturbance of
calcium handling related to ryanodine receptors [16], which
are one of the targets of autoimmunity in patients with MG
[1]. A large-scale, long-term study is needed for verification,
while the mechanism and clinical significance of diastolic
dysfunction also remain to be elucidated.
There are several limitations of the present study. First,
not all the patientswithMGunderwent ECGand echocardio-
graphic examinations at our hospital and a selection bias may
exist. Therefore, further prospective large-scale study or the
analysis of consecutive cases is warranted to validate ECG as a
useful tool for the screeningmethod of cardiac dysfunction in
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Table 2: Clinical characteristics of patients with myasthenia gravis.
With ECG abnormality (𝑛 = 33) Without ECG abnormality (𝑛 = 25) 𝑝 value
Male, 𝑛 (%) 15 (48.4) 9 (50.6) 0.903
Age, mean ± SD, y 60 ± 5.2 58 ± 6.1 0.67
Time from diagnosis, mean ± SD, y 12 ± 8.0 11 ± 7.1 0.67
Thymoma, 𝑛 (%) 8 (24.2) 10 (40) 0.08
Comorbidities, 𝑛
Diabetes mellitus 1 2
Systemic lupus 1 2
Rheumatoid arthritis 0 1
Sjogren disease 0 1
Death, 𝑛 3 3 0.512
Cause of death, 𝑛
Malignancy 1 2
Heart failure 1
Acute myocardial infarction 1
Aplastic anemia 1
Type of treatment, 𝑛 (%)
Steroid 19 (55.4) 10 (40.0)
Cholinesterase inhibitor 14 (34.5) 7 (28.0)
Immunosuppressant 12 (34.2) 11 (44.0)
ECG: electrocardiography; LV: left ventricle.
Table 3: Echocardiographic parameters of patients with myasthenia gravis.
With ECG abnormality (𝑛 = 33) Without ECG abnormality (𝑛 = 25) 𝑝 value
Ejection fraction (%) 61.2 ± 15.1 66.1 ± 4.8 0.16
LV end-diastolic dimension (mm) 44.7 ± 5.8 47.6 ± 7.3 0.14
LV end-systolic dimension (mm) 31.8 ± 9.5 28.4 ± 4.3 0.90
Septal wall thickness (mm) 8.9 ± 1.6 8.8 ± 1.1 0.63
𝐸/𝑒
󸀠 11.2 ± 3.2 8.7 ± 2.2 0.03
Left atrium diameter (mm) 36.5 ± 6.6 34.1 ± 5.6 0.20
Wall motion abnormality 5; diffuse 0
LV: left ventricle.












reduced EF) 27 33
(𝑛) 20 38 58
all patients with MG. Second, coronary artery disease could
not be excluded entirely in these patients with MG, even
though regional abnormality of wall motion, consistent with
coronary artery disease, was not found in the present study.
Third, whether an exercise test provoked the reduction of EF
was not verified in the present study. BNP (or N-terminal
pro-BNP) levels and physical findings were inadequate to be
acquired. However, due to the rarity of the MG with cardiac
involvement, this retrospective study has a clinical insight for
the detection of systolic or diastolic dysfunction in patients
with MG.
5. Conclusions
ECG may aid as the first step for the further examination of
cardiac damage in patients with MG.
Conflict of Interests
The authors report no relationships that could be construed
as a conflict of interests.
Authors’ Contribution
Takao Kato and Sayako Hirose conceived and designed the
experiments. TakaoKato, SayakoHirose, and ShogoKumagai
analyzed the data. Takao Kato wrote the paper. Akihiko
4 BioMed Research International
Ozaki, Sadayuki Matsumoto, and Moriaki Inoko critically
reviewed the paper.
Acknowledgment
This study was supported by the Tazuke Kofukai Medical
Research Institute.
References
[1] H. Hofstad, O.-J. Ohm, S. J. Mork, and J. A. Aarli, “Heart disease
in myasthenia gravis,” Acta Neurologica Scandinavica, vol. 70,
no. 3, pp. 176–184, 1984.
[2] S. Suzuki, K. Utsugisawa, H. Yoshikawa et al., “Autoimmune
targets of heart and skeletal muscles in myasthenia gravis,”
Archives of Neurology, vol. 66, no. 11, pp. 1334–1338, 2009.
[3] M. J. L. de Jongste, H. J. G. H. Oosterhuis, and K. I. Lie,
“Intractable ventricular tachycardia in a patient with giant cell
myocarditis, thymoma and myasthenia gravis,” International
Journal of Cardiology, vol. 13, no. 3, pp. 374–378, 1986.
[4] S. Kumagai, T. Kato, A. Ozaki et al., “Letter to the editor: serial
measurements of cardiac troponin i in patients withmyasthenia
gravis-related cardiomyopathy,” International Journal of Cardi-
ology, vol. 168, no. 2, pp. e79–e80, 2013.
[5] E. Venturini, A. Pellegrinetti, C. Marabotti, L. Magni, and R.
Testa, “Myasthenia gravis and heart failure: is ivabradine a
useful drug?” International Journal of Cardiology, vol. 174, no.
1, pp. e4–e6, 2014.
[6] R. J. Prineas, R. S. Crow, and H. Blackburn, The Minnesota
Code Manual of Electrocardiographic. Findings: Standards and
Procedures for Measurement and Classification, John Wright,
PSG, Boston, Mass, USA, 1982.
[7] J. A. Kors, R. S. Crow, P. J. Hannan, P. M. Rautaharju, and A. R.
Folsom, “Comparison of computer-assigned Minnesota codes
with the visual standardmethod for new coronary heart disease
events,” American Journal of Epidemiology, vol. 151, no. 8, pp.
790–797, 2000.
[8] Japanese Circulation Society, “Guidelines for the clinical appli-
cation of echocardiography,” Circulation Journal, vol. 69, pp.
1409–1445, 2005.
[9] C. W. Yancy, M. Jessup, B. Bozkurt et al., “2013 ACCF/AHA
guideline for the management of heart failure: a report of the
American College of Cardiology Foundation/American Heart
Association Task Force on Practice Guidelines,” Journal of the
American College of Cardiology, vol. 62, no. 16, pp. e147–e239,
2013.
[10] S. F. Nagueh, C. P. Appleton, T. C. Gillebert et al., “Rec-
ommendations for the evaluation of left ventricular diastolic
function by echocardiography,” Journal of the American Society
of Echocardiography, vol. 22, no. 2, pp. 107–133, 2009.
[11] B.-Y. Xu, R. Pirskanen, and A. Kari Lefvert, “Antibodies against
𝛽1 and 𝛽2 adrenergic receptors in myasthenia gravis,” Journal of
Neuroimmunology, vol. 91, no. 1-2, pp. 82–88, 1998.
[12] T. C. Gibson, “The heart in myasthenia gravis,” American Heart
Journal, vol. 90, no. 3, pp. 389–396, 1975.
[13] L. Ingle, J. G. Cleland, and A. L. Clark, “The long-term prognos-
tic significance of 6-minute walk test distance in patients with
chronic heart failure,” BioMed Research International, vol. 2014,
Article ID 505969, 7 pages, 2014.
[14] S. R. Ommen, R. A. Nishimura, C. P. Appleton et al., “Clin-
ical utility of Doppler echocardiography and tissue Doppler
imaging in the estimation of left ventricular filling pressures:
a comparative simultaneous Doppler-catheterization study,”
Circulation, vol. 102, no. 15, pp. 1788–1794, 2000.
[15] S. F. Nagueh, I. Mikati, H. A. Kopelen, K. J. Middleton,
M. A. Quin˜ones, and W. A. Zoghbi, “Doppler estimation of
left ventricular filling pressure in sinus tachycardia. A new
application of tissue Doppler imaging,” Circulation, vol. 98, no.
16, pp. 1644–1650, 1998.
[16] V. A. Lacombe, S. Viatchenko-Karpinski, D. Terentyev et
al., “Mechanisms of impaired calcium handling underlying
subclinical diastolic dysfunction in diabetes,” The American
Journal of Physiology—Regulatory Integrative and Comparative
Physiology, vol. 293, no. 5, pp. R1787–R1797, 2007.



















































 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
